Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer
量化和个性化转移定向治疗对患有新发寡转移性前列腺癌的男性的临床益处
基本信息
- 批准号:10153007
- 负责人:
- 金额:$ 51.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-14 至 2027-11-30
- 项目状态:未结题
- 来源:
- 关键词:AblationAddressAfrican AmericanAftercareAmericanAndrogen ReceptorBioinformaticsBiological MarkersBiometryBiopsyBiopsy SpecimenBloodBlood CellsCancer EtiologyCastrationCessation of lifeClinicalClinical ManagementClinical TrialsCollectionCountryDataDiagnosisDiseaseEnrollmentExtramural ActivitiesFOLH1 geneFailureGenomicsGoalsHeterogeneityHistologicImageIncidenceIndividualInternationalIntramural Research ProgramMalignant NeoplasmsMalignant neoplasm of prostateMetastatic Prostate CancerModelingMolecularMolecular ProfilingNeoplasm Circulating CellsNeoplasm MetastasisNewly DiagnosedNorth AmericaPET/CT scanPatientsPatternPhasePositron-Emission TomographyPrognostic MarkerProstatectomyQuality of lifeRadiation therapyRadical ProstatectomyRandomizedRandomized Controlled TrialsReceptor SignalingRecording of previous eventsResearchResistanceResourcesSamplingSiteSpecimenSystemic TherapyTestingTherapeutic TrialsTimeTissuesTranslationsUnited KingdomUnited States National Institutes of HealthValidationWorkX-Ray Computed Tomographyarmbiomarker signaturebone imagingburden of illnesscell free DNAchemotherapyclinical centerexomeexperiencefeature extractionimaging biomarkerimaging modalityimaging programimprovedinhibitor/antagonistliquid biopsymenmolecular imagingmolecular markermolecular subtypesneoplastic cellnext generationnovelpatient biomarkerspersonalized medicinephase II trialphase III trialpredicting responsepredictive markerprimary endpointprospectiveprostate biopsyradiomicsrandomized trialresponseresponse biomarkerstandard of caretranscriptometreatment response
项目摘要
Project Summary/Abstract
The long-term goal of this project is to determine the clinical impact of metastasis-directed radiotherapy (MDT)
in men with de novo oligometastatic prostate cancer (PCa), and identify which men may be cured and benefit
most from MDT. We aim to achieve this goal through the conduct of a phase 3 randomized controlled trial with
prospective imaging and biospecimen (e.g. tissue and blood) collection. This trial is novel in that it is a
randomized North American sub-study (n=200) of the next arm (Arm M) of the international landmark multi-
arm, multi-stage, STAMPEDE trial. The ability to conduct this trial with comprehensive biospecimen collection
and imaging analysis will be achieved through our unique research team across extramural and intramural
centers, comprised of experts in prognostic and predictive biomarker signature identification, bioinformatics,
biostatistics, genomics, imaging, and clinical trial execution. We will leverage the opportunity for North America
to participate in the STAMPEDE trial to not simply identify the true impact of MDT in the first ever large phase 3
trial testing MDT in PCa, but use this one of a kind clinical trial working with the NCI to develop the first
predictive biomarkers of benefit of MDT using radiomics of conventional and molecular PET imaging, as well
as sequencing of primary, metastatic, and liquid biopsies. This goal will be carried out through three specific
aims. Aim 1 will focus on the conduct of the phase 3 randomized North American sub-study to determine if the
addition of MDT to standard systemic therapy and treatment of the primary improves failure-free survival. Five
centers will participate, including the NIH Clinical Center. These patients will all be included in the international
STAMPEDE trial with the primary endpoint of overall survival. Aim 2 will leverage the baseline CT and bone
scans collected on all patients, as well as a subset that will be sent to the NCI to have pre-treatment 18F-
DCFPyL PET/CT scans performed (n=50). Radiomic analyses and image feature extraction will be performed,
and this information will be used to identify which men benefit most from MDT. We hypothesize that a subset
of men will benefit most from MDT and be identifiable through an imaging biomarker. Aim 3 will utilize the
baseline prostate biopsy, metastatic biopsies, radical prostatectomy specimens, and liquid biopsies (circulating
tumor cells and cell-free DNA), to annotate the molecular landscape of oligometastatic PCa. This data will
then be used to develop a predictive biomarker to identify which men benefit most from MDT. International
patient samples will be banked for later validation. We hypothesize that a discrete molecular profile will
characterize which men are most likely to be cured from MDT. The impact of this work is extremely large, as it
has the potential to cure a currently incurable subset of men with metastatic PCa. Successful completion of
these aims would result in predictive biomarkers that could directly impact the clinical management of men with
oligometastatic PCa, and transform current treatment paradigms.
项目摘要/摘要
该项目的长期目标是确定转移定向放射治疗(MDT)的临床影响。
对新发的少转移前列腺癌(PCa)男性进行研究,并确定哪些男性可以治愈并受益
大多数来自MDT。我们的目标是通过进行第三阶段随机对照试验来实现这一目标
前瞻性成像和生物样品(如组织和血液)采集。这场审判很新颖,因为它是一场
对具有国际里程碑意义的MARM的下一个ARM(ARM)的随机北美分研究(n=200)
ARM,多阶段,踩踏试验。使用全面的生物样品收集进行这项试验的能力
图像分析将通过我们独特的研究团队在壁外和壁内实现
中心,由预测和预测生物标记物特征识别、生物信息学、
生物统计学、基因组学、成像和临床试验执行。我们将利用北美的机遇
参与踩踏试验,而不是简单地确定MDT在有史以来第一个大型第三阶段的真正影响
在PCA中试验MDT,但使用这种与NCI合作的临床试验来开发第一个
使用常规和分子PET成像的放射组学预测MDT受益的生物标志物
作为对原发、转移和液体活检的测序。这一目标将通过三个具体的途径来实现
目标。目标1将侧重于进行第三阶段随机北美分研究,以确定
在标准的系统治疗和原发肿瘤治疗的基础上增加MDT可提高无失败存活率。五
包括NIH临床中心在内的中心将参与其中。这些患者都将被包括在国际
以总体生存为主要终点的踩踏试验。目标2将利用基线CT和骨骼
在所有患者身上收集的扫描,以及将被发送到NCI进行治疗前18F-
DCFPyL PET/CT扫描(n=50)。将执行放射学分析和图像特征提取,
这些信息将被用来确定哪些男性从MDT中受益最大。我们假设有一个子集
的男性将从MDT中受益最大,并可通过成像生物标记物进行识别。目标3将利用
基线前列腺活检、转移性活检、根治性前列腺切除术标本和液体活检(循环
肿瘤细胞和无细胞DNA),以诠释少转移性前列腺癌的分子图景。此数据将
然后被用来开发一种预测性生物标记物,以确定哪些男性从MDT中受益最大。国际
患者样本将被储存起来,以供以后验证。我们假设一个离散的分子轮廓将
确定哪些男性最有可能从MDT中治愈。这项工作的影响是非常大的,因为它
有可能治愈目前无法治愈的转移性前列腺癌患者。成功完成
这些目标将导致预测性生物标志物的产生,这些生物标志物可能直接影响男性患者的临床治疗
少转移性前列腺癌,并改变目前的治疗模式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel Eidelberg Spratt其他文献
Daniel Eidelberg Spratt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
African American (AA) Communities Speak: Partnering with AAs in the North and South to Train Palliative Care Clinicians to Address Interpersonal and Systemic Racism and Provide Culturally Aligned Care
非裔美国人 (AA) 社区发言:与北部和南部的 AA 合作,培训姑息治疗临床医生,以解决人际和系统性种族主义并提供文化一致的护理
- 批准号:
10734272 - 财政年份:2023
- 资助金额:
$ 51.33万 - 项目类别:
GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging young African American women in a virtual group app to address alcohol misuse, sexual risk, and PrEP in NC
GODDESS(在线聚集进行对话和讨论,以加强社会支持):让年轻的非裔美国女性参与虚拟团体应用程序,以解决北卡罗来纳州的酒精滥用、性风险和 PrEP 问题
- 批准号:
10541028 - 财政年份:2022
- 资助金额:
$ 51.33万 - 项目类别:
GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging young African American women in a virtual group app to address alcohol misuse, sexual risk, and PrEP in NC
GODDESS(在线聚集进行对话和讨论,以加强社会支持):让年轻的非裔美国女性参与虚拟团体应用程序,以解决北卡罗来纳州的酒精滥用、性风险和 PrEP 问题
- 批准号:
10684239 - 财政年份:2022
- 资助金额:
$ 51.33万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10395616 - 财政年份:2021
- 资助金额:
$ 51.33万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10786490 - 财政年份:2021
- 资助金额:
$ 51.33万 - 项目类别:
Reducing Hypertension among African American Men: A Mobile Stress Management Intervention to Address Health Disparities
减少非裔美国男性的高血压:解决健康差异的移动压力管理干预措施
- 批准号:
10821849 - 财政年份:2021
- 资助金额:
$ 51.33万 - 项目类别:
Reducing Hypertension among African American Men: A Mobile Stress Management Intervention to Address Health Disparities
减少非裔美国男性的高血压:解决健康差异的移动压力管理干预措施
- 批准号:
10384110 - 财政年份:2021
- 资助金额:
$ 51.33万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10336591 - 财政年份:2021
- 资助金额:
$ 51.33万 - 项目类别:
Community-Academic Partnerships to Address COVID-19 Inequities within African American Communities
社区学术伙伴关系解决非裔美国人社区内的 COVID-19 不平等问题
- 批准号:
10245326 - 财政年份:2021
- 资助金额:
$ 51.33万 - 项目类别:
Building a Multidisciplinary Research Program to Address Hypertension Disparities:Exploring the Neurocognitive Mechanisms of a Self-Management Intervention for African American Women with Hypertension
建立一个多学科研究计划来解决高血压差异:探索非裔美国高血压女性自我管理干预的神经认知机制
- 批准号:
10334538 - 财政年份:2019
- 资助金额:
$ 51.33万 - 项目类别: